Monoclonal Antibodies & Paxlovid Antiviral
We offer monoclonal antibodies and Paxlovid antiviral prescriptions at our clinic. When you arrive for your appointment, our medical provider will review your symptoms and the options for treatment with you.
Innovative Care has Bebtelovimab monoclonal antibody treatments at our COVID clinic. Treatments should be initiated as soon as possible after diagnosis of COVID-19 and within seven days of symptom onset. Treatments are administered via an IV infusion and are effective against the Omicron strain and Omicron BA.2 variant. These lab-made antibodies serve as substitute antibodies that help our immune systems mimic the defense of natural COVID-19 antibodies, which have been determined to reduce serious infection and death. They are FDA EUA approved treatments for COVID-19. Review the FDA patient fact sheet for Bebtelovimab for more information.
Currently, Innovative Care has decided to use Bebtelovimab, the newest monoclonal antibody that has been shown to reliably bind to the spike protein of the BA.2 variant (the current dominant variant in the Chicagoland area).
Paxlovid is an FDA EUA approved oral medication for the treatment of mild to moderate COVID-19. It is available by prescription only for patients age 12 and older. Paxlovid should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset. We have Paxlovid medication stocked at our COVID testing and treatment clinic (1111 W Diversey Parkway) and at our urgent care (2400 N Ashland Avenue). If our provider prescribes Paxlovid, you will take the medication home with you immediately.
Who qualifies for treatment?
COVID treatment is now more widely available in Chicago, so there are fewer restrictions when it comes to who should be treated. When you arrive for your appointment, our medical provider will assess your risk factors for severe complications from COVID-19 and help you determine which treatment is right for you. You qualify for treatment if:
- You are age 65 or older
- You are under 65 with one of the following risk factors:
- Overweight (body mass index over 25)
- Former smoker
- High blood pressure
- Any history of heart disease or stroke
- Hispanic or Black
- Have not had your booster shot (often known as 3rd dose)
- Kidney or liver disease
- Diabetes (Type 1 and Type 2)
- Weakened immune system
- Currently receiving immunosuppressive treatment
- Chronic lung disease
- Sickle cell disease
- Neurodevelopmental disorders
- Medical-related technological dependence
For those who do not fit the above criteria, we feel it is important to still make an appointment and talk to our provider, who will go into your history thoroughly and make a personalized plan with you.
Innovative COVID accepts most major insurance plans, and 90 percent of people who get this treatment will not get a bill or pay for the evaluation for antivirals or monoclonal antibody treatment. Based on our experience, approximately five percent of patients will be required by their insurer to pay a co-pay (usually $40 or less). Another 5 percent will receive a bill for monoclonal medication infusion (usually about $350 after insurance).
If you do not have any medical insurance, you will be asked to self-pay for your COVID treatment. The cost for each treatment is as follows: Monoclonal antibody treatment ($350), Paxlovid ($150), Evusheld ($250). You may be able to submit your receipt for reimbursement if you have a healthcare spending account.
1111 W DIVERSEY PKWY, CHICAGO IL 60614
136 OGDEN AVENUE, DOWNERS GROVE IL 60515
COVID Treatment FAQ
We carry the Paxlovid medication at our clinic, so you’ll take the medication home with you immediately (no trip to the pharmacy). There is no charge for this medication at Innovative Care.
Innovative Care has Bebtelovimab monoclonal antibody treatments at our COVID clinic.
Monoclonal antibodies are administered via an IV infusion. The appointment lasts about 90 minutes and begins with an evaluation from our emergency medicine physician or provider. Patients who schedule an appointment are under no obligation to have the infusion. Furthermore, treatment will not be administered if the patient does not meet the risk criteria.
After entering your body, monoclonal antibodies look for and attach to the spike protein that sticks out of the coronavirus that causes COVID-19. When monoclonal antibodies attach to the spike protein, they can block the virus’s ability to enter cells, thereby slowing down the infection. More information about the EUA approved COVID treatments and fact sheets for the various monoclonal antibody medications can be found here.